Valye reports for unlimited access

SKYX Platforms Corp. is a Florida-incorporated company specializing in advanced-safe-smart platform technologies for electrical products such as light fixtures and ceiling fans. Its technology enables quick, safe plug-and-play installation without handling hazardous wiring. The company has evolved its product offerings to include smart features controlled via mobile applications, enhancing home safety and convenience. SKYX also markets third-party home lighting and furnishings. The company operates primarily in the United States with additional presence in China. It holds multiple patents and has engaged in strategic partnerships to expand its market reach. SKYX has a history of operating losses but has raised capital through equity offerings and convertible notes to support operations and growth initiatives [S1].

Fusemachines Inc. is an enterprise AI solutions provider offering a suite of AI products and services designed to help organizations integrate AI into their operations. Its core offerings include AI Studio, a platform for building and managing AI applications; AI Engines, specialized AI software targeting industry-specific challenges; and AI Agents, intelligent systems automating complex workflows. The company complements its products with services such as customization, model tuning, deployment, and bespoke AI solution development. Fusemachines also operates AI training programs to address the global shortage of skilled AI professionals. The company completed a business combination in 2025, becoming publicly traded. Its client base spans diverse industries including consumer brands, healthcare, media, technology, and government. Fusemachines holds intellectual property assets including patent applications and employs various IP protection strategies. The company reported $7.7 million in revenue and a net loss of $928,000 for the fiscal year ended December 31, 2025, with liquidity ratios indicating constrained short-term financial flexibility. It faces competition from internal corporate IT teams, commercial AI software providers, open-source platforms, cloud providers, and system integrators. Sales cycles are lengthy and resource-intensive, with customer concentration risk present. The company emphasizes human capital management, compliance, and intellectual property protection as key operational pillars.

Utah Medical Products, Inc. (UTMD) produces and markets a broad range of medical devices primarily used in critical care hospital settings such as neonatal intensive care units, labor and delivery departments, and women's health centers, as well as outpatient clinics and physician offices. The company emphasizes device safety, improved patient outcomes, and cost-effectiveness. UTMD's business model involves direct sales to clinical end-users and stocking distributors in the U.S., and direct sales plus independent distributors internationally, covering countries including Canada, UK, France, Ireland, Australia, and New Zealand. The company also manufactures components and finished devices on a subcontract basis for other medical device companies (OEM sales). UTMD has expanded through acquisitions and maintains manufacturing and distribution facilities in the U.S., Ireland, UK, Australia, Canada, and New Zealand. The company invests in product development focused on device improvements, new product introductions, and acquisitions or licensing of technology. UTMD holds multiple patents and trademarks, with trademarks providing significant brand recognition. The company faces competition from multiple competitors for each device type, competing primarily on clinical benefits and device reliability. UTMD's marketing strategy includes direct sales representatives, consultants, and manufacturer representatives focused on clinical applications and customer training. The company is exposed to risks from trade disruptions, tariffs, foreign currency fluctuations, and restricted access to clinicians in the U.S. market [S1].

DICK'S Sporting Goods, Inc. is a leading sporting goods retailer operating multiple store formats and an omni-channel platform. The company offers a broad assortment of products including exclusive vertical brand merchandise, which accounts for about 13% of sales in its DICK'S Business segment. It has expanded its retail experience through new store concepts featuring interactive and experiential elements. The company sources products from approximately 1500 vendors, with Nike as its largest supplier. It operates a global distribution and fulfillment network to support its stores and eCommerce operations. The company is actively integrating the Foot Locker Business as a standalone segment, aiming to leverage operational synergies. Its business is sensitive to macroeconomic factors affecting consumer discretionary spending and faces competitive pressures across retail channels. The company manages risks related to supply chain, inventory, regulatory compliance, and technological innovation.

Air Industries Group is a publicly traded company listed on the NYSE American exchange under the ticker AIRI. The company reported approximately $47.9 million in revenue for the full year 2025 and a net loss of $1.305 million. Its liquidity position as of the end of 2025 shows a current ratio of 1.24, indicating moderate short-term financial stability. The company has been involved in legal proceedings related to a sublease agreement, which it is contesting and does not currently expect to materially impact its financial condition. In February 2026, Air Industries Group entered into a merger agreement with Tenax Aerospace Acquisition, LLC, which involves issuing shares and creating a subsidiary. Recent quarterly financial results have shown losses but revenue exceeding estimates, and the company’s stock has experienced notable price fluctuations relative to the broader market.

Spartacus Acquisition Corp. II is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in November 2025. Its business model is to identify, acquire, and merge with one or more target businesses in any industry, thereby taking the combined entity public. The company completed its IPO in February 2026, raising $230 million, which is held in a trust account to fund the initial business combination. The management team has extensive experience in technology, media, and telecommunications sectors and aims to leverage their expertise and network to source and execute a business combination. The company has no operating revenues or selected target as of the latest filing and must complete the business combination within 24 months of the IPO or liquidate. The company’s structure offers target businesses an alternative to traditional IPOs, potentially providing a faster and more cost-effective path to public markets. The company faces competition from other SPACs and investment groups in sourcing suitable targets.

Daedalus Special Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in August 2025 in the Cayman Islands. It was formed to effect a merger or similar business combination with one or more businesses, with an initial focus on the consumer artificial intelligence (AI) sector. The company completed its IPO in December 2025, issuing 25 million units at $10 each, raising gross proceeds of $250 million, plus a private placement of 685,000 units raising $6.85 million. Proceeds are held in a trust account until an initial business combination is completed or the company liquidates. The management team includes seasoned professionals with experience in AI, mobile applications, gaming, financial technology, and capital markets. The company’s strategy is to acquire and scale a leading consumer AI company with a profitable subscription-driven model, leveraging operational expertise and pursuing market consolidation through acquisitions. The company has not yet selected a business combination target and has not initiated substantive discussions with any target. Financial snapshot as of December 31, 2025, shows current assets of $1.14 million, current liabilities of $0.2 million, a current ratio of 5.8, and net income of $370,459. The company currently has three officers and no full-time employees prior to a business combination.

SIM Acquisition Corp. I is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. The company has no operating history or revenues and is focused on identifying and completing an initial business combination with a target company. It is not limited to any particular industry or sector for its business combination. The company’s financial position as of December 31, 2025, shows limited current assets and liabilities, with a current ratio below 1. The company has disclosed substantial risks related to its ability to complete a business combination within the required timeframe, including competition for targets, regulatory challenges, and potential dilution from additional share issuances or debt. The company’s public shareholders have limited voting rights on the business combination, and founder shares may influence the outcome. The company has entered into administrative agreements and issued a promissory note to its sponsor for working capital. It is listed on Nasdaq under the ticker SIMA and is classified as an emerging growth company.

Knightscope, Inc. designs, manufactures, and leases Autonomous Security Robots (ASRs) and sells Electronic Control Devices (ECDs) alongside installation, maintenance, and upgrade services. The company’s business model includes recurring revenue from ASR leases and maintenance contracts, as well as product sales. Revenue recognition follows lease accounting for ASRs and point-in-time or over-time recognition for ECD sales and services. The company’s revenue for 2025 was $11.3 million, with service revenue comprising 70% and product revenue 30%. Despite revenue growth, Knightscope reported a gross loss and net loss for the year, reflecting high costs and investments in research and development. The company maintains liquidity with cash and equivalents of $20.6 million and a strong current ratio but continues to operate at a loss and requires additional financing to sustain operations. Supply chain challenges and customer concentration are notable operational factors. The company’s backlog stood at approximately $3.1 million as of March 2026 [S1].

Tenon Medical, Inc. develops and commercializes medical devices for the treatment of sacroiliac (SI) joint disorders, a significant cause of chronic lower back pain. The company offers two main systems: The Catamaran SI Joint Fusion System, a less invasive, single titanium implant approach cleared by the FDA in 2018 and commercially launched nationally in 2022, and the SImmetry + System, acquired in 2025, which uses a minimally invasive lateral access technique with 3D printed titanium implants. Tenon targets a U.S. market estimated at 270,000 annual SI Joint surgical procedures, currently underserved with 5-7% penetration. The company distributes products primarily through independent sales representatives to approximately 12,000 physicians specializing in spine and pelvic surgeries. Tenon emphasizes clinical outcomes such as pain reduction, patient satisfaction, and radiographic confirmation of fusion, supported by prospective clinical studies. The company faces supply chain risks due to reliance on a limited number of contract manufacturers without long-term agreements. Financially, Tenon reported $3.94 million in revenue and a net loss of $12.56 million for fiscal 2025, with liquidity ratios indicating moderate short-term financial health. The company recently raised approximately $4.3 million through convertible promissory notes and is addressing Nasdaq listing compliance due to its stock price falling below $1.00 per share.

Crown Reserve Acquisition Corp. I is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in April 2025. Its business model is to raise capital through an IPO and private placement to fund a future Business Combination with one or more target companies. The company completed its IPO in November 2025, issuing 17.25 million units and raising $172.5 million, which was placed in a Trust Account invested in short-term U.S. government securities. The company has no operations or employees and focuses on identifying a suitable acquisition target within a defined Combination Period of 12 months, extendable to 15 months. Management brings broad experience in technology, financial services, healthcare technology, and consumer sectors, with expertise in mergers and capital markets. The company’s securities trade on Nasdaq under multiple symbols representing shares, warrants, rights, and units. The company’s financial position as of December 31, 2025, shows net income of approximately $1.13 million and limited liquidity outside the Trust Account. The company faces typical SPAC risks including execution risk, competition for targets, and potential dilution.

Launchpad Cadenza Acquisition Corp I is a special purpose acquisition company (SPAC) incorporated in June 2025 in the Cayman Islands. Its business purpose is to identify and complete a Business Combination with one or more companies, focusing on technology and software infrastructure businesses within blockchain, fintech, and digital assets ecosystems. The company completed its IPO in December 2025, issuing 23 million Units at $10 each, raising $230 million placed in a Trust Account. The Management Team and Advisors have extensive experience in fintech and SPAC transactions. The company has not yet selected a Business Combination target and has no operating revenues. It aims to complete a Business Combination by December 19, 2027, or liquidate and return funds to shareholders if unsuccessful. The company maintains strong liquidity with a current ratio of 12.58 as of the end of 2025 and reported a small net income for the fiscal year 2025.

Abony Acquisition Corp. I is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in November 2025. It was formed to identify and complete a merger or similar business combination with one or more target companies, focusing on businesses with enterprise values between $750 million and $1.5 billion in sectors such as defense technology, advanced computing, software, and media. The company completed its initial public offering in February 2026, raising gross proceeds of $230 million, which are held in a trust account to fund the business combination. The company has not commenced operations or generated revenues and incurs costs related to administration and preparation for the business combination. The management team brings extensive experience in scaling public companies, capital markets, and SPAC transactions. The company has a 24-month window to complete its initial business combination, with possible extensions subject to shareholder approval.

Functional Brands Inc. operates in the nutraceutical supplement industry, manufacturing and distributing dietary supplements across multiple health categories. Its principal business is conducted through the Kirkman division, which offers over 150 products including vitamins, probiotics, enzymes, and specialty supplements. The company markets products through pharmacies, wholesalers, international distributors, and direct-to-consumer channels, including online platforms. It has a significant customer relationship with iHerb, accounting for a substantial portion of revenue. The company has expanded its offerings with the launch of the P2i by Kirkman certified prenatal vitamin and the Tru2u.health digital health platform, which integrates telehealth services and wellness supplements. Functional Brands completed a Nasdaq direct listing in November 2025 and has engaged in capital restructuring involving convertible preferred stock. The company maintains manufacturing in an FDA registered, cGMP certified facility in Oregon and emphasizes product purity and quality standards.

1606 Corp. was incorporated in Nevada in 2021 as a spin-off from Singlepoint Inc. Initially engaged in selling tobacco- and nicotine-free hemp cigarettes, the company discontinued that business and pivoted in 2023 to AI chatbot technology focused on the CBD industry. The company developed proprietary AI chatbots, including 'chatCBDW' for CBD retailers and 'IRChat' for public companies, delivered via a monthly licensing fee model. 1606 Corp. leverages independent sales organizations to distribute its chatbot solutions. The company has a team with extensive AI and technology experience and owns intellectual property related to its chatbot technology. In late 2025 and early 2026, 1606 Corp. began acquiring power generation and data center infrastructure assets in Texas to support AI and data center operations, including a 55 MW power generation facility and a 50,000 square foot climate-controlled warehouse on 132 acres. The company has not yet secured full financing for these acquisitions and has no prior experience operating power generation or data center facilities. The company reported no revenue and a net loss for the fiscal year ended 2025, with limited liquidity and significant current liabilities. The CEO is the sole full-time employee, supported by contractors and consultants. The company is headquartered in Phoenix, Arizona.

SPACSphere Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands, designed to raise capital through an IPO to acquire or merge with one or more operating businesses. The company completed its IPO in February 2026, issuing 17.25 million units and raising $172.5 million in gross proceeds, which are held in a trust account invested in low-risk U.S. government securities. The company has not yet selected any acquisition targets and is not restricted to any industry or geography. Its management team brings extensive experience in business growth, investment, and acquisitions. The company’s acquisition criteria emphasize competitive positioning, management quality, growth potential, and risk-adjusted returns. The company has a single reportable segment and has incurred net losses related to administrative expenses since inception.

PAVmed Inc. operates as a diversified life sciences company with a focus on medical devices, diagnostics, and digital health through independently financed subsidiaries. Its primary subsidiaries are Lucid Diagnostics, which commercializes the EsoGuard Esophageal DNA Test and EsoCheck device for early detection of esophageal precancer and cancer, and Veris Health, which provides a digital cancer care platform aimed at improving personalized cancer care and monitoring. PAVmed also develops medical devices such as the PortIO implantable intraosseous vascular access device and licensed endoscopic imaging technology. The company pursues commercialization through multiple channels, including physician offices, test centers, telemedicine, and direct contracting with employers and health systems. It actively seeks reimbursement coverage and has secured contracts such as the U.S. Department of Veterans Affairs agreement for EsoGuard. Veris Health operates on a SaaS recurring revenue model with strategic partnerships at academic oncology centers. PAVmed's regulatory strategy includes FDA Breakthrough Device Designation and CE Mark certifications. The company faces competition from established and emerging players in diagnostics and digital health, and it manages liquidity constraints with ongoing capital raising efforts.

Soulpower Acquisition Corp. is a Cayman Islands exempted company operating as a Special Purpose Acquisition Company (SPAC) listed on the New York Stock Exchange under the ticker SOUL. The company has entered into a definitive business combination agreement with SWB LLC, a Cayman Islands limited liability company, to form a new public company. This transaction aims to create a new economy financial services conglomerate, including a stablecoin-denominated AI bank under the brand SOUL WORLD BANK™. The combined entity plans to operate as a licensed international financial institution with diverse financial lines and tokenized asset offerings. The business combination agreement was signed on November 24, 2025, with a pre-money valuation of approximately $8.1 billion based on contributed assets. The company has filed a confidential draft registration statement on Form S-4 with the SEC as part of the regulatory process. Financially, as of December 31, 2025, Soulpower reported current assets of approximately $1.5 million and current liabilities of approximately $1.68 million, resulting in a current ratio below 1. The company reported net income of about $6 million for the fiscal year ended December 31, 2025, and basic and diluted earnings per share of -$0.02 for the first quarter of 2025. The business combination remains subject to shareholder approval and regulatory clearances. The company is classified as an emerging growth company and has issued unsecured promissory notes to support working capital needs.

Presidio Property Trust, Inc. is a publicly traded, internally-managed REIT incorporated in Maryland, owning a portfolio of commercial real estate and model home properties across multiple U.S. states. The commercial portfolio includes office, industrial, and retail properties leased to a diversified tenant base, while the model home portfolio consists of single-family model homes leased back to homebuilders under triple-net leases. The company focuses on acquiring stabilized or near-stabilized properties in regionally dominant markets with favorable economic and demographic trends. It operates several affiliated limited partnerships for its model home business and provides management services to these entities. The company pursues value creation through selective acquisitions, dispositions, and active portfolio management, including share repurchase programs and capital raising initiatives.

BioXcel Therapeutics, Inc. operates as a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines primarily in neuroscience and immuno-oncology. The company’s proprietary AI platform, EvolverAI, identifies new therapeutic indications by analyzing existing drugs and clinical data to reduce development costs and timelines. Its lead neuroscience product, BXCL501, marketed as IGALMI®, is FDA-approved for acute treatment of agitation in schizophrenia and bipolar I or II disorder, with ongoing clinical development for at-home use. The immuno-oncology pipeline includes BXCL701, an investigational oral innate immune activator targeting aggressive cancers. BioXcel relies on third-party manufacturers and clinical trial operators. The company faces extensive regulatory requirements and market acceptance challenges. As of December 31, 2025, BioXcel reported a net loss and negative earnings per share, with liquidity ratios below 1, indicating current liabilities exceed current assets.

Alussa Energy Acquisition Corp. II is a Cayman Islands exempted blank check company incorporated in August 2024. Its purpose is to identify and complete a business combination with one or more companies primarily in the energy and power infrastructure sectors, with a focus on renewable energy transition. The company completed its IPO in November 2025, raising gross proceeds of $287.5 million, which are held in a Trust Account to fund the initial Business Combination. The company has not yet identified a target and has no operating revenues. The management team has extensive experience in energy, capital markets, and SPAC transactions, including prior successful business combinations. The company aims to acquire businesses with enterprise values between $1.0 billion and $1.5 billion but may consider other sizes. It must complete the Business Combination by November 14, 2027, or liquidate and return funds to shareholders. The company reported a net loss of $7.4 million for 2025, driven by advisory fees and administrative costs, partially offset by interest income from the Trust Account. As of December 31, 2025, it had a current ratio of 4.62, indicating strong liquidity.

Manhattan Bridge Capital, Inc. is a specialized real estate finance company that originates, services, and manages a portfolio of short-term, secured first mortgage loans primarily in the New York metropolitan area and Florida. The loans are typically for one year, secured by residential or commercial real estate, and personally guaranteed by borrower principals. The company operates as a REIT, distributing at least 90% of taxable income to shareholders. It maintains credit facilities with Webster Bank, Flushing Bank, and Valley National Bank to support its lending activities. The company emphasizes disciplined underwriting, flexible loan structuring, and quick execution to serve small real estate developers and investors. Its loan portfolio is concentrated but diversified across residential, commercial, and mixed-use properties. The company has a history of capital preservation with minimal foreclosures and focuses on generating attractive risk-adjusted returns primarily through dividends.

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel cancer immunotherapies, including oncolytic virus platforms. The company manages its operations as a single segment encompassing research, development, and commercialization activities. Its product candidates are in various stages of preclinical and clinical development, including CLD-101 for recurrent glioma, CLD-201 for solid tumors, and CLD-401 with clinical trials initiated in Australia. Calidi has not yet generated commercial revenues and depends on capital raises to fund its operations. The company operates subsidiaries in Germany and Australia to support clinical trial activities. It is classified as an emerging growth company and smaller reporting company, which affords certain regulatory reporting exemptions. The company faces typical early-stage biotech risks including long development cycles, regulatory approvals, and capital requirements [S1][N1][N8].

GD Culture Group Ltd is a company focused on live-streaming e-commerce primarily on the TikTok platform. It discontinued its online livestreaming gaming business in early 2025. The company has pursued growth through strategic acquisitions, including Pallas Capital Holding, and capital raising activities such as private placements and a significant common stock purchase agreement aimed at enhancing its crypto asset treasury strategy. GD Culture holds substantial Bitcoin assets as part of its treasury. The company relies heavily on TikTok for its business operations, including inventory management and live streaming channels. It faces competition in the emerging TikTok live-streaming e-commerce market, which is currently less intense than in Asian markets but expected to become more competitive. GD Culture has not established a history of recurring operating revenues and depends on capital raises and future revenue generation to sustain operations. The company is subject to regulatory risks in the PRC, cybersecurity threats, and operational risks related to e-commerce fraud and employee conduct. It is a smaller reporting company with reduced disclosure requirements and has announced a share repurchase program to return value to shareholders [S1][S2][N1][N2][N3][N4][N5][N6][N8].

Vale S.A. is a multinational mining company engaged in the extraction, processing, and sale of iron ore, pellets, nickel, copper, and other base metals. The company operates globally with a significant customer base in Asia, particularly China, as well as in the Americas and Europe. Its business segments include Iron Ore Solutions and Vale Base Metals, each contributing to revenue and profitability through production volumes and commodity prices. Vale's operations include mining, logistics, and energy production related to its core mining activities. The company invests in sustaining and growth capital expenditures and manages remediation obligations related to past dam failures. Vale maintains a diversified shareholder base and complies with financial covenants on its debt. It also implements comprehensive executive compensation programs aligned with performance and shareholder interests.

Frontline plc is a shipping company specializing in oil tankers, including VLCCs and Suezmax vessels. The company operates in a cyclical market influenced by global oil supply and demand dynamics. It finances its fleet through a combination of cash from operations, equity capital, and bank borrowings. Frontline maintains liquidity through cash reserves and revolving credit facilities. The company has recently updated its fleet by selling older vessels and acquiring newbuildings with advanced environmental features. Governance is conducted under Cyprus law with some differences from NYSE standards. The company has established robust internal controls and cybersecurity measures. Recent operational updates include new time charter agreements and dividend declarations.

Biodexa Pharmaceuticals Plc, headquartered in Cardiff, UK, is a clinical-stage biopharmaceutical company developing treatments primarily for gastrointestinal cancers such as gastrointestinal stromal tumors (GIST) and familial adenomatous polyposis (FAP). The company transitioned from a drug delivery focus to therapeutics in early 2023, concentrating on clinical-stage assets. Its lead asset, eRapa, is a proprietary oral formulation of rapamycin designed to improve bioavailability and reduce toxicity, currently in a Phase 3 trial for FAP. The company also licensed MTX240, a molecular glue therapeutic candidate for GIST, from Otsuka Pharmaceutical in 2026, with plans for early clinical development. Tolimidone is in Phase 2a development for type 1 diabetes. Biodexa relies on contract manufacturing and intends to license products to partners for late-stage development and commercialization. The company has received significant grant funding to support its clinical programs and has recently restructured its operations, including decommissioning its Cardiff laboratory.

ARBE Robotics Ltd. operates in the technology sector, focusing on software infrastructure for autonomous vehicle radar systems. The company develops AI-powered radar platforms designed to support Level 4 autonomous driving applications such as robotaxis, robotrucks, and commercial off-road vehicles. ARBE combines its radar technology with NVIDIA AI computing to create advanced autonomous driving solutions. The company is headquartered in Tel Aviv-Yafo, Israel, and actively engages in capital raising through convertible bonds and direct offerings to support its growth and product development. Leadership changes were announced in early 2026, with a new CEO appointed effective April 1, 2026.

Silo Pharma, Inc. operates primarily in the biopharmaceutical sector, developing novel therapeutics targeting underserved conditions such as PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system diseases. The company’s product pipeline includes candidates containing controlled substances like psilocybin and ketamine, which are subject to stringent regulatory oversight by the FDA, DEA, and other authorities. Silo Pharma has recently expanded its business model to include digital asset investments, including a $1 million Bitcoin purchase as a treasury reserve asset. The company has engaged in partnerships and joint ventures, notably with Hoth Therapeutics to commercialize a VA-invented obesity drug, and with Resyca BV for drug-device studies targeting PTSD treatment. Financially, the company reported limited revenue and a net loss for the fiscal year ended December 31, 2025, but maintains strong liquidity with a current ratio above 11. The company is listed on Nasdaq but faces compliance challenges related to minimum bid price requirements. Silo Pharma’s business model involves navigating complex regulatory environments for controlled substances and digital assets, with ongoing clinical development and capital raising activities.

KBS Real Estate Investment Trust III, Inc. is a publicly reporting Maryland corporation electing REIT status, conducting business primarily through its wholly owned Operating Partnership. The company’s investment portfolio as of December 31, 2025, consists of 12 core office properties across the United States and an equity investment in a Singapore real estate investment trust. The company’s business model focuses on acquiring, managing, and disposing of office real estate assets to maximize long-term value for stakeholders. The company’s advisor, KBS Capital Advisors, manages day-to-day operations and portfolio management, providing asset management, disposition, marketing, investor relations, and administrative services. The company has no paid employees. The company’s loan agreements impose requirements to sell certain properties to meet debt maturities and principal paydowns, with refinancing and restructuring efforts ongoing amid challenging market conditions. The company’s governance includes oversight of cybersecurity risks and incident response. The company’s financial statements are prepared on a going concern basis due to market uncertainties and liquidity challenges [S1][S2].

Autolus Therapeutics plc develops, manufactures, and commercializes programmed T cell therapies targeting cancer and autoimmune diseases. Its lead commercial product, AUCATZYL (obe-cel), is a CD19-directed CAR T cell therapy approved for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). The company launched AUCATZYL in the US in January 2025 and in the UK in January 2026 following regulatory approvals and NHS recommendation. Autolus is advancing obe-cel in pediatric oncology and autoimmune indications including lupus and multiple sclerosis, supported by ongoing clinical trials. The company utilizes proprietary modular T cell programming technologies such as fast off-rate CARs, dual-targeting CARs, pharmacological safety switches, and tumor microenvironment shielding to improve efficacy and safety. Manufacturing is conducted at the Nucleus facility in the UK, with commercial distribution partnerships in the US. Autolus has incurred significant operating losses but maintains liquidity to support operations. Revenue recognition follows ASC 606 and CMS coding policies for split dosing. The company faces competition in CAR T therapies and regulatory, pricing, and supply chain risks.

SAMFINE CREATION HOLDINGS GROUP Ltd operates principally through its subsidiaries in Hong Kong and the PRC, providing a broad range of printing services and products including books, packaging, and personalized printing. The company generates sales on an order-by-order basis without long-term contracts, with customer demand influenced by economic conditions. It maintains a dual-class share structure with a controlling shareholder holding significant voting power. The company has experienced recent trading halts and resumptions due to volatility. Financially, it reported increased revenue and a return to profit in interim results in late 2024, with a net loss reported for the full year 2025. Liquidity ratios indicate the company maintains coverage of current liabilities by current assets. The company does not currently pay dividends and retains earnings for operational and expansion purposes.

Aptorum Group Ltd is a clinical stage biopharmaceutical company dedicated to developing therapeutic and diagnostic products addressing unmet medical needs, particularly in oncology and infectious diseases. The company focuses on advancing lead projects ALS-4 and SACT-1, having streamlined operations by terminating clinic services and suspending non-lead R&D projects to optimize resource allocation. Aptorum pursues collaborations with academic institutions and contract research organizations, leverages government grants, and selectively expands its portfolio with potential orphan drug designations. The company is engaged in a merger agreement with DiamiR, a molecular diagnostics company specializing in neurodegenerative diseases and cancer diagnostics, with the merger and related agreements extended through mid-2026. Financially, Aptorum reported a net loss and reduced R&D spending in 2025, with liquidity constrained as indicated by a current ratio below 1. The company is addressing a material weakness in internal controls related to finance and accounting resources.

uCloudlink Group Inc. is a technology company specializing in cloud SIM technology that enables global mobile data connectivity. Its core offering is the uCloudlink cloud SIM platform, which manages a distributed pool of SIM cards and data plans, allowing users and business partners to access optimized mobile data services across multiple networks and geographies. The company generates revenue from data connectivity services, sales of hardware terminals such as GlocalMe portable Wi-Fi devices, and PaaS and SaaS services that support business partners' operations. It also offers IoT modules targeting enterprise customers in sectors like security and automotive. uCloudlink's business model involves partnerships with mobile network operators, MVNOs, and portable Wi-Fi rental companies. The company markets its products through online and offline channels, including global exhibitions and retail partnerships. Financially, uCloudlink reported $81.4 million in revenue and $6.3 million in net income for 2025, with a solid liquidity position. However, it operates in a complex regulatory environment in China, facing potential tax classification risks and Nasdaq listing volatility.

LogicMark, Inc. develops and markets personal emergency response systems (PERS), health communications devices, and IoT technology designed to support independent living and remote care. The company’s product portfolio includes no monthly fee devices and monitored devices with monthly fees, sold through multiple channels including direct-to-consumer, healthcare providers, and business-to-business. LogicMark maintains a significant relationship with the U.S. Veterans Health Administration and holds a renewable five-year GSA contract enabling sales to government entities. The company leverages AI and machine learning to enhance predictive health monitoring capabilities. Recent product launches and expansions into Medicaid waiver programs reflect ongoing efforts to broaden market access and product offerings.

Bogota Financial Corp. was formed in 2019 as the holding company for Bogota Savings Bank following a mutual holding company reorganization. The bank operates primarily in New Jersey with seven branch offices and a loan production office. Its lending portfolio is concentrated in one- to four-family residential real estate loans, commercial real estate loans, and multi-family real estate loans, with smaller exposure to consumer, commercial and industrial, and construction loans. The bank competes in a crowded market with larger regional and money center banks, credit unions, and non-depository financial service providers. It is regulated by the New Jersey Department of Banking and Insurance, the Federal Reserve Board, and the FDIC. The company has undertaken strategic balance sheet restructuring including sale-leaseback transactions. As of the end of 2025, the bank was well capitalized and had a loan portfolio totaling approximately $650 million.